arrow
P

Peter K. Kaiser

Cleveland Clinic Foundation
H指数:82
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes and Complications of Pars Plana Vitrectomy for Non-clearing Vitreous Hemorrhage without Tractional Elements

玻璃体切除术治疗无牵引元件的非清除玻璃体出血的结果和并发症

2026-01-290
PREAI
Real-World Functional and Anatomic Outcomes With Aflibercept 8.0 mg in Patients With Diabetic Macular Edema

Barbosa, G.C.S.; Bala, S.; Mohan, N.; Srivastava, S.K.; Kaiser, P.K.; Sastry, A.; Babiuch, A.S.; Sears, J.; Talcott, K.E.; Yuan, A.; 等. 糖尿病黄斑水肿患者使用Aflibercept 8.0 mg的实世界功能和解剖学结局。J. Vitreoretin. Dis. 2025, 10, 74–82. [Google Scholar] [CrossRef]

2026-01-011
PRE
OphthoEvidence report: Baseline structural optical coherence tomography biomarkers predictive of visual acuity following epiretinal membrane surgery-A systematic review and meta-analysis protocol

OphthoEvidence报告:玻璃体黄斑前膜手术后视力预后的基线结构光学相干断层扫描生物标志物——系统评价与Meta分析方案

2025-12-160
PRE
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

阿瓦辛卡帕德·贝戈尔(Avacincaptad pegol)用于年龄相关性黄斑变性继发的地理性萎缩:GATHER2三期试验2年的疗效和安全性结果

2025-12-150
OAAI
Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review

与光学相干断层扫描生物标志物相关的糖尿病黄斑水肿的视觉结局:一项系统综述

2025-09-170
PREAI
Baseline Optical Coherence Tomography Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-Analysis

基线光学相干断层扫描生物标志物与糖尿病黄斑水肿视力相关性的系统评价和Meta分析

2025-08-110
OAAI
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation

Recland-2: 一项随机II期临床试验,评估了Elamipretide在与年龄相关的黄斑变性,地理萎缩的生长,视觉功能和椭圆体区域的保存

2025-01-013
OAAI
International Classification System for Ocular Complications of Anti-VEGF Agents in Clinical Trials
2024-12-010
OA
Bispecific VEGF-A and Angiopoietin-2 Antagonist RO-101 Preclinical Efficacy in Model of Neovascular Eye Disease
2024-07-010
OAAI
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
LANCET
IF88.5
2023-10-0184
OAAI